# Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors

> **NCT01421004** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 166 (actual)

## Conditions studied

- Advanced Solid Tumors
- Excluding Breast Cancer

## Interventions

- **DRUG:** TKI258

## Key facts

- **NCT ID:** NCT01421004
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2014-07
- **Final completion:** 2014-07
- **Target enrollment:** 166 (ACTUAL)
- **Last updated:** 2020-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01421004

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01421004, "Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01421004. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*